While other review articles have focused much on summarizing the result of these clinical trials and providing meta-analysis findings in detail, our approach would highlight time stamps of these notable clinical trials while providing a brief summary of the findings that led to further investigation to provide a holistic picture and overview of why SGLT2 inhibitors transitioned from a drug initially used for diabetes to an established HF medication. The gene discussed is SLC5A2; the disease is diabetes mellitus.